BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 21196168)

  • 1. Chronic viral hepatitis: epidemiology, molecular biology, and antiviral therapy.
    Gonzalez SA; Keeffe EB
    Front Biosci (Landmark Ed); 2011 Jan; 16(1):225-50. PubMed ID: 21196168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidemiology, Natural History, and Treatment of Hepatitis Delta Virus Infection in HIV/Hepatitis B Virus Coinfection.
    Ferrante ND; Lo Re V
    Curr HIV/AIDS Rep; 2020 Aug; 17(4):405-414. PubMed ID: 32607773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Diagnosis and treatment of chronic hepatitis B and D. Hungarian national consensus guideline].
    Horváth G; Hunyady B; Gervain J; Lengyel G; Makara M; Pár A; Szalay F; Telegdy L; Tornai I
    Orv Hetil; 2014 Mar; 155 Suppl():25-36. PubMed ID: 24631887
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does antiviral therapy reduce the risk of hepatocellular carcinoma in patients with chronic hepatitis C?
    Michielsen P; Ho E; Francque S
    Minerva Gastroenterol Dietol; 2012 Mar; 58(1):65-79. PubMed ID: 22419005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of hepatitis B and C in children.
    El-Shabrawi M; Hassanin F
    Minerva Pediatr; 2014 Oct; 66(5):473-89. PubMed ID: 25253190
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Antiviral therapy and risk for hepatocellular carcinoma in chronic viral hepatitis].
    Abdurakhmanov DT
    Ter Arkh; 2013; 85(10):94-7. PubMed ID: 24437226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
    Harada N; Hiramatsu N; Oze T; Tatsumi T; Hayashi N; Takehara T
    J Med Virol; 2015 Jul; 87(7):1199-206. PubMed ID: 25772024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Protocol for the treatment of chronic viral hepatitis].
    Dalmi L; Gervain J; Hunyady B; Ibrányi E; Makara M; Pár A; Szalay F; Tornai I; Telegdy L
    Orv Hetil; 2006 Dec; 147(51):2481-4. PubMed ID: 17378168
    [No Abstract]   [Full Text] [Related]  

  • 9. PegIFN-α2a for the treatment of chronic hepatitis B and C: a 10-year history.
    Degasperi E; Viganò M; Aghemo A; Lampertico P; Colombo M
    Expert Rev Anti Infect Ther; 2013 May; 11(5):459-74. PubMed ID: 23627852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Protocol for the treatment of chronic viral hepatitis].
    Dalmi L; Gervain J; Horváth G; Hunyady B; Ibrányi E; Makara M; Pár A; Szalay F; Tornai I; Telegdy L; ;
    Orv Hetil; 2008 Jan; 149(3):129-35. PubMed ID: 18194921
    [No Abstract]   [Full Text] [Related]  

  • 12. Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin.
    Todorovska B; Joksimovic N; Caloska-Ivanova V; Dimitrova-Genadieva M; Trajkovska M; Curakova E; Kiprijanovska S; Zafirova-Ivanovska B; Serafimoski V
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2017 Mar; 38(1):25-33. PubMed ID: 28593897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
    Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
    J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral dominance patterns in chronic hepatitis delta determine early response to interferon alpha therapy.
    Lutterkort GL; Wranke A; Hengst J; Yurdaydin C; Stift J; Bremer B; Hardtke S; Keskin O; Idilman R; Manns MP; Dienes HP; Falk C; Wedemeyer H; Heidrich B
    J Viral Hepat; 2018 Nov; 25(11):1384-1394. PubMed ID: 29888837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marked reduction of the alpha-fetoprotein levels among individuals with chronic hepatitis C, following PEG-interferon and ribavirin treatment.
    Aladag M; Camci C; Huang Y; Wright H; Rizvi S; Gurakar A; Stokes K; Sebastian A
    J Clin Gastroenterol; 2005; 39(10):923-4. PubMed ID: 16208125
    [No Abstract]   [Full Text] [Related]  

  • 16. Interferon-based therapy delays but metabolic comorbidity accelerates progression of chronic hepatitis C.
    Martínez-Macías RF; Cordero-Pérez P; Juárez-Rodríguez OA; Chen-López CY; Martínez-Carrillo FM; Alarcón-Galván G; Mercado-Hernández R; Muñoz-Espinosa LE
    Ann Hepatol; 2015; 14(1):36-45. PubMed ID: 25536640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
    Shiffman ML; Morishima C; Dienstag JL; Lindsay KL; Hoefs JC; Lee WM; Wright EC; Naishadham D; Everson GT; Lok AS; Di Bisceglie AM; Bonkovsky HL; Ghany MG;
    Gastroenterology; 2009 Dec; 137(6):1986-94. PubMed ID: 19747918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
    Potthoff A; Deterding K; Trautwein C; Rifai K; Manns MP; Wedemeyer H
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):906-9. PubMed ID: 17873617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin.
    Moon C; Jung KS; Kim DY; Baatarkhuu O; Park JY; Kim BK; Kim SU; Ahn SH; Han KH
    Dig Dis Sci; 2015 Feb; 60(2):573-81. PubMed ID: 25236421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.